Brain Health

Tune into this special episode of “Public Health Matters” to hear Emma White, the founder and president of the nonprofit organization Life Is Worth It, discuss her mental health journey and how she used it to educate adolescents, teenagers, and young adults on mental wellness.

The treatment is the first liquid non-stimulant for attention deficit hyperactivity disorder to be approved in the United States.

Data have shown the potential for the therapy to treat several new conditions.

Experts emphasize the importance of awareness when using social media and make suggestions on how to combat the spread of misinformation and conspiracy theories.

Results from the INCREASE study shed light on the value of the pharmacist in medication therapy management.

The authors note that this finding may have promise for use in assessing mental health conditions and improving patient outcomes.

A clinical pharmacist discusses his work in the mental health space while stressing the importance of advocating for and checking in with one another’s emotional well-being.

Compared with women who aren’t experiencing menopausal symptoms, women in the perimenopause stage were approximately 40% more likely to experience depressive symptoms.

According to the speaker, the complexity of immune-related adverse events resulting from immune checkpoint inhibitors requires a lot of collaborative discussion between patients and providers.

Speakers in a presentation discuss a specific patient with MS who experienced urinary complications and the methods used to treat her.

Tovorafenib is the first systemic therapy to be approved for the treatment of pediatric patients who have low-grade glioma with BRAF rearrangements or fusions.

Speaker Monica Diaz describes the detrimental impact climate change has on the transmission and increases in infectious disease cases.

The product is currently being investigated alongside TLX101 in the IPAX-Linz and IPAX-2 clinical trials, and have previously shown efficacy in the IPAX-1 trial.

If approved, the test could provide more timely and accurate diagnosis, hopefully mitigating the impact of Alzheimer disease (AD) on individuals and the community.

The study is the first of 5 studies co-published by AYR Wellness and LECOM and showcases improvements in physical, social, and mental well-being with minimal AEs.

The campaign for National Stress Awareness Month in April is under way.

Aged mice displayed improvements in their spatial cognition, short-term memory, and muscle durability.

A study about modifiable risk factors on a “weak spot” in the brain network found that diabetes, pollution, and alcohol were most likely to contribute to dementia disorders.

The recent ODD for the utidelone injectable could offer another treatment option for patients with BCBM.

The results displayed a dramatic reduction in the individuals’ tumors within days after single treatment.

Case reports have shown a potential association with adverse psychological effects.

The findings also indicated that individuals who experienced significant adverse events in childhood were approximately 17% more likely to experience adverse events in adulthood.

The device conducts blood biomarker tests that accurately diagnose amyloid pathology and can assist in diagnosing Alzheimer disease in patients with cognitive impairment.

The CBT-based intervention, compared with routine pregnancy care, demonstrated reductions of 81% and 74% for depression and anxiety, respectively.

Using deep brain simulation, study authors identified networks in the brain that can be used to better treat Parkinson disease, dystonia, Tourette syndrome, and OCD.

Hypomyelination with atrophy of the basal ganglia and cerebellum is the most severe form of TUBB4A leukodystrophy that currently has no curative treatment.

The dynamic reconfigurations in individuals taking antidepressant were higher than in non-users and controls, with no significant differences between those with MDD or an anxiety disorder.

Sustained cognitive improvement is likely a result of lower inflammation, remission of comorbidities, higher physical activity, and better mood.

The authors emphasize that further research on a diverse population that focuses on the role of duration and lifestyle choices and neuroinflammatory markers should be performed.

Despite the tool’s ability to predict efficacy of sertraline in patients with major depressive disorder, the investigators note that future research will seek to improve the algorithm.